Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
暂无分享,去创建一个
T. Krivak | J. Kelley | R. Edwards | K. Zorn | T. Beck | Sarah E Taylor | R. Edwards
[1] A. Jemal,et al. Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.
[2] M. Shahin,et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.
[3] B. Dörken,et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.
[4] M. Saif,et al. Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review , 2010, Metal-based drugs.
[5] A. Kotanidou,et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. , 2010, Inflammation & allergy drug targets.
[6] A. Grothey,et al. Phase 2 Trial of Docetaxel, Gemcitabine, and Oxaliplatin Combination Chemotherapy in Platinum- and Paclitaxel-Pretreated Epithelial Ovarian Cancer , 2009, International Journal of Gynecologic Cancer.
[7] T. Hickish,et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Robert S Mannel,et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Piccart,et al. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma , 2008, Archives of Gynecology and Obstetrics.
[10] A. Norman,et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. , 2008, The New England journal of medicine.
[11] Michael W Sill,et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] A. Oza,et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer , 2007, Current oncology.
[13] N. Petrelli,et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Thomssen,et al. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. , 2007, Gynecologic oncology.
[15] S. Waggoner,et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.
[16] T. Conroy,et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Robert S Mannel,et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Morgan,et al. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] V. Torri,et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial , 2003, The Lancet.
[20] P. Rose,et al. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.
[21] J. Essigmann,et al. Mechanisms of resistance to cisplatin. , 2001, Mutation research.
[22] P. Chollet,et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] R. Ozols,et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Vance,et al. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. , 1994, Gynecologic oncology.
[25] S. Rubin,et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] J. Berek,et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] E. Yordan,et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study , 1986, Cancer.
[28] D. Mavroudis,et al. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). , 2008, Anticancer research.